Kezar Life Sciences Terminates Material Agreement
Ticker: KZR · Form: 8-K · Filed: Oct 22, 2025 · CIK: 1645666
| Field | Detail |
|---|---|
| Company | Kezar Life Sciences, INC. (KZR) |
| Form Type | 8-K |
| Filed Date | Oct 22, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $6.3 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: termination, agreement
Related Tickers: KZR
TL;DR
Kezar Life Sciences (KZR) terminated a key deal on Oct 20th. Details TBD.
AI Summary
Kezar Life Sciences, Inc. announced on October 20, 2025, the termination of a material definitive agreement. The filing does not specify the counterparty or the nature of the agreement, but it is classified under Item Information as a termination.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's operations, financial standing, and future strategic direction.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement often signals significant business changes or disputes that could affect the company's financial health and stock price.
Key Players & Entities
- Kezar Life Sciences, Inc. (company) — Registrant
- October 20, 2025 (date) — Date of earliest event reported
- 4000 Shoreline Court, Suite 300 (address) — Principal Executive Offices
- South San Francisco, California 94080 (address) — Principal Executive Offices
FAQ
What specific material definitive agreement was terminated by Kezar Life Sciences?
The filing does not specify the name or details of the material definitive agreement that was terminated.
Who was the counterparty to the terminated material definitive agreement?
The filing does not disclose the identity of the other party involved in the terminated agreement.
What is the effective date of the termination of the material definitive agreement?
The earliest event reported, which includes the termination, is dated October 20, 2025.
What is the business impact of this termination on Kezar Life Sciences?
The filing does not provide details on the specific business impact of the termination.
Is this termination related to any specific product or research program of Kezar Life Sciences?
The filing does not contain information linking the termination to any specific product or research program.
Filing Stats: 478 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2025-10-22 16:19:14
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value KZR The Nasdaq Stock Market L
- $6.3 million — using cash on hand, made a repayment of $6.3 million in full satisfaction of the aggregate o
Filing Documents
- kzr-20251020.htm (8-K) — 24KB
- 0001628280-25-045871.txt ( ) — 183KB
- kzr-20251020.xsd (EX-101.SCH) — 3KB
- kzr-20251020_def.xml (EX-101.DEF) — 16KB
- kzr-20251020_lab.xml (EX-101.LAB) — 29KB
- kzr-20251020_pre.xml (EX-101.PRE) — 17KB
- kzr-20251020_htm.xml (XML) — 4KB
02 Termination of a Material Definitive Agreement
Item 1.02 Termination of a Material Definitive Agreement. On October 20, 2025, Kezar Life Sciences, Inc. (the "Company"), using cash on hand, made a repayment of $6.3 million in full satisfaction of the aggregate outstanding amount, including accrued interest and exit fees as of such date, under the Loan and Security Agreement (the "Loan Agreement"), dated as of November 4, 2021, among the Company, as borrower, Oxford Finance LLC, as collateral agent, and the lenders party thereto. The Loan Agreement was terminated in accordance with the terms of a payoff letter and all liens and security interests granted thereunder to secure the obligations were released.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEZAR LIFE SCIENCES, INC. Date: October 22, 2025 By: /s/ Marc L. Belsky Marc L. Belsky Chief Financial Officer and Secretary